CNS Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CNSP | PCSA | BIVI | NIKI | 18H0.F | NRSN | |
|---|---|---|---|---|---|---|
| Market cap | 6.34M | 5.41M | 11.63M | 5.27M | 5.11M | 2.69M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -11.1 | -0.5 | -2.4 | — | — | -0.3 |
| Price/book | 0.3 | -17.0 | 1.0 | 0.1 | -1.1 | -1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −33.30% | −75.51% | −10.67% | −87.62% | −25.00% | −93.11% |
| Today | −4.62% | −0.26% | −22.54% | −3.98% | −23.81% | +9.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CNSP news ›CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors
CNS Pharmaceuticals, Inc. announced that it has entered into a Securities Purchase Agreement pursuant to which the company will issue 650,000 common shares at $0.001 par value per share at an issue... announced that it has entered into a…
CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
CNS Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2026 for the period ending Dec 31, 2025. In this report its auditor, Malone & Bailey, PLLC, gave an unqualified opinion expressing doubt that the... Biotechnology & Medical Research CNS…
CNS Pharmaceuticals, Inc. Announces Chief Medical Officer Changes, Effective March 2, 2026
CNS Pharmaceuticals, Inc. announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer, effective March 2, 2026. Dr. Kelley, age 63, most recently served as Chief Medical Officer of... announced the appointment of Lynne…
Transcript : CNS Pharmaceuticals, Inc. - Special Call
Presenter SpeechJenene Thomas Welcome back, and thank you for joining us for our latest Virtual Investor What This Means segment. Today, we are featuring CNS Pharmaceuticals. My name is Jenene Transcript : CNS Pharmaceuticals, Inc. -…
CNS Pharmaceuticals, Inc.: Relative Strength Chart - Stock Nasdaq
Compare CNS Pharmaceuticals, Inc. with the company of your choice via a Relative Strength chart. Real-time CNSP price, Nasdaq stock exchange Relative Strength Chart CNS Pharmaceuticals, Inc. Biotechnology & Medical Research All financial…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.